戻る Agenda
Session 5: Education
Session Chair(s)
Hillel P Cohen, PhD
Executive Director, Scientific Affairs
Sandoz Inc., United States
Because the US approval pathway for biosimilars and interchangeable biologics is relatively new, it is important to ensure appropriate information about these products is available for those making critical decisions about prescribing or their own treatment options. In this session, an assessment of the current understanding of US health care professionals and the public of the concepts of biosimilars and interchangeable biologics will provide insights into the areas for which education is needed. Ongoing and future programs designed by a patient advocacy group and a professional society for their memberships will illustrate varied approaches to accomplishing goals for biosimilar education.
Speaker(s)
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Dorothy A McCabe, PhD
Boehringer-Ingelheim, United States
Executive Director
Biosimilars Education - Patient Needs and Perspectives
Samantha Roberts, PhD
Genentech, A Member of the Roche Group, United States
Group Director, US Regulatory Science
AMCP Initiatives on Biosimilars Education
Mary Jo Carden, JD, RPh
Sandoz, Inc., United States
Head, Policy
Panel Discussion
All Session Speakers, United States
Panelist
Leah Christl, PhD
Amgen, United States
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy